Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice

被引：30
|
作者：
Lees, CJ
Apostolopoulos, V
Acres, B
Ramshaw, I
Ramsay, A
Ong, CS
McKenzie, IFC
机构：
[1] Austin Res Inst, Melbourne, Vic 3084, Australia
[2] Victoria Univ Technol, Ctr Bioproc & Food Technol, Werribee, Vic 3030, Australia
[3] Transgene SA, Dept Immunobiol, F-67082 Strasbourg, France
[4] Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol, Canberra, ACT 2601, Australia
来源：
VACCINE | 2000年 / 19卷 / 2-3期
关键词：
cytokines; transgenic; MUC1;
D O I：
10.1016/S0264-410X(00)00065-7
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8(+) cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic;mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：158 / 162
页数：5
相关论文
共 50 条
  • [21] Expression of Human MUC1 During Early Pregnancy in the Human MUC1 Transgenic Mouse Model
    Dharmaraj, Neeraja
    Gendler, Sandra J.
    Carson, Daniel D.
    BIOLOGY OF REPRODUCTION, 2009, 81 (06) : 1182 - 1188
  • [22] MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice
    Lakshminarayanan, Vani
    Supekar, Nitin T.
    Wei, Jie
    McCurry, Dustin B.
    Dueck, Amylou C.
    Kosiorek, Heidi E.
    Trivedi, Priyanka P.
    Bradley, Judy M.
    Madsen, Cathy S.
    Pathangey, Latha B.
    Hoelzinger, Dominique B.
    Wolfert, Margreet A.
    Boons, Geert-Jan
    Cohen, Peter A.
    Gendler, Sandra J.
    PLOS ONE, 2016, 11 (01):
  • [23] Prevention of Inflammation-Driven Colon Carcinogenesis in Human MUC1 Transgenic Mice by Vaccination with MUC1 DNA and Dendritic Cells
    Murwanti, Retno
    Denda-Nagai, Kaori
    Sugiura, Daisuke
    Mogushi, Kaoru
    Gendler, Sandra J. J.
    Irimura, Tatsuro
    CANCERS, 2023, 15 (06)
  • [24] MUC1 as a target antigen for cancer immunotherapy
    Acres, B
    Limacher, JM
    EXPERT REVIEW OF VACCINES, 2005, 4 (04) : 493 - 502
  • [25] Liposomal delivery of a MUC1 lipopeptide overcomes tolerance and induces antitumor immunity in MUC1-transgenic mice
    Samuel, J
    Wang, D
    Gendler, SJ
    Longenecker, BM
    FASEB JOURNAL, 2000, 14 (06): : A1006 - A1006
  • [26] Local Effects of Regulatory T Cells in MUC1 Transgenic Mice Potentiate Growth of MUC1 Expressing Tumor Cells In Vivo
    Sugiura, Daisuke
    Denda-Nagai, Kaori
    Takashima, Mitsuyo
    Murakami, Ryuichi
    Nagai, Shigenori
    Takeda, Kazuyoshi
    Irimura, Tatsuro
    PLOS ONE, 2012, 7 (09):
  • [27] Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice
    Curry, Jennifer M.
    Besmer, Dahlia M.
    Erick, Timothy K.
    Steuerwald, Nury
    Das Roy, Lopamudra
    Grover, Priyanka
    Rao, Shanti
    Nath, Sritama
    Ferrier, Jacob W.
    Reid, Robert W.
    Mukherjee, Pinku
    PLOS ONE, 2019, 14 (11):
  • [28] Lung Injury Model Using Human MUC1 Transgenic Mice
    Sakai, M.
    Kubota, T.
    Isaka, M.
    Yamane, T.
    Shiota, N.
    Ohnishi, H.
    Iwamoto, H.
    Yokoyama, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [29] In vitro kinetic analysis of cellular anti-MUC1 immune responses in MUC1 transgenic mice.
    VanLith, ML
    Tempero, RM
    Gendler, SJ
    Hollingsworth, MA
    FASEB JOURNAL, 1998, 12 (05): : A891 - A891
  • [30] Parameters for using mannan-MUC1 fusion protein to induce cellular immunity
    G. A. Pietersz
    Wenjun Li
    Violeta Popovski
    Julie-Anne Caruana
    Vasso Apostolopoulos
    Ian F. C. McKenzie
    Cancer Immunology, Immunotherapy, 1998, 45 : 321 - 326
12345